Evidence map›Paper›PMID 28793307›Full record

ArticlePLoS neglected tropical diseases2017

Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri.

Bharat Bashyal, Linfeng Li, Trpta Bains, Anjan Debnath, Daniel V LaBarbera

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A systematic review of anti-Parasitology · 2021
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Phytochemical Compounds and Pharmacological Properties ofMolecules (Basel, Switzerland) · 2022
    Review
  7. Molecules (Basel, Switzerland) · 2022
    Article
  8. Opportunistic free-living amoebal pathogens.Pathogens and global health · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Synthesis, Characterization, andBioMed research international · 2020
    Article
  14. Antioxidants (Basel, Switzerland) · 2019
    Article
  15. Article
  16. Assessing the Antioxidant Properties ofMolecules (Basel, Switzerland) · 2018
    Article
  17. Article
  18. Flavonoids as a Natural Treatment AgainstFrontiers in cellular and infection microbiology · 2018
    Review
  19. Highly Potent 1Frontiers in cellular and infection microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bharat BashyalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Linfeng LiDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Trpta BainsCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Daniel V LaBarberaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.ORCID http://orcid.org/0000-0001-9460-3862

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Novel Therapeutics Against Diabetic Eye DiseaseR01EY021498 · NEI · UNIVERSITY OF COLORADO DENVER · PI LABARBERA, DANIEL V., PETRASH, JONATHAN MARK · 2011 to 2015
$2.1M
NCATS NIH HHS KL2 TR001444NEI NIH HHS R01 EY021498
6 · The paper itself

Abstract

Protozoan parasites infect and kill millions of people worldwide every year, particularly in developing countries where access to clean fresh water is limited. Among the most common are intestinal parasites, including Giardia lamblia and Entamoeba histolytica. These parasites wreak havoc on the epithelium lining the small intestines (G. lamblia) and colon (E. histolytica) causing giardiasis and amebiasis, respectively. In addition, there are less common but far more deadly pathogens such as Naegleria fowleri that thrive in warm waters and infect the central nervous systems of their victims via the nasal passages. Despite their prevalence and associated high mortality rates, there remains an unmet need to identify more effective therapeutics for people infected with these opportunistic parasites. To address this unmet need, we have surveyed plants and traditional herbal medicines known throughout the world to identify novel antiparasitic agents with activity against G. lamblia, E. histolytica, and N. fowleri. Herein, we report Larrea tridentata, known as creosote bush, as a novel source for secondary metabolites that display antiparasitic activity against all three pathogens. This report also characterizes the lignan compound classes, nordihydroguairetic acid and demethoxyisoguaiacin, as novel antiparasitic lead agents to further develop more effective drug therapy options for millions of people worldwide.

Indexed as

Antiprotozoal AgentsEntamoeba histolyticaGiardia lambliaHumansLarreaMasoprocolNaegleria fowleriNaphtholsPlant ExtractsAntiprotozoal AgentsdemethoxyisoguaiacinMasoprocolNaphtholsPlant Extracts

Identifiers

PMID28793307
PMCPMC5565192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.